Ann: ITL Appendix 4E & Annual Report 2017, page-2

First impression, although revenue up only by 12%. GROSS PROFIT is up by 40%. assuming it is due to higher profit margin in the ITL bio medical comp, also the foreign currency earner, this department has expanded revenue by more than 23% YOY. it is the current jewel in the crown and where growth is expected
in the near future. employee expenses have gone up dramatically and may be due to the expansion into the New MY HEALTH TEST segment. also encouraging for share holders is the % of shares held by founder + Managment, most hold shares, all up 46 mil, accounting for nearly half of shares. I am satisfied.
THANK YOU to ITL management and workers, GOOD LUCK to all